BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Russia's Veropharma a Target of $636 Million Buyout?


11/12/2012 11:23:57 AM

Shares in Russian pharmaceutical companies 36.6 and Veropharm surged in Monday afternoon trading on the Moscow Stock Exchange on news the competition watchdog had cleared Sistema conglomerate to buy up to 100 percent of Veropharm. As of 2:51 p.m. Moscow time (11:51 a.m. GMT), shares in the 36.6 pharmacy retail chain jumped 6.7 percent while the stock of Russia’ third largest drugmaker Veropharm soared 9.7 percent compared with a 0.2 percent fall in the MICEX stock index. The Federal anti-Monopoly Service announced on Monday it had allowed Sistema, a diversified holding company with interest ranging from oil to communications to buy up to 100 percent of the voting stock of Veropharm. “The Federal Anti-Monopoly Service had made a decision to meet this petition [from Sistema] and simultaneously issue prescriptions to both Sistema and Veropharm to accomplish measures aimed at ensuring competition. This decision is effective only in conjunction with these prescriptions,” the watchdog said in a statement.

Read at News Release
Read at Bloomberg

Veropharm
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->